Radiolabelled chemotherapeutics

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 51, Issue 2, 2007, Pages 139-151

  Rottey, S ^a   Signore, A ^b,c   Van de Wiele, Christophe ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Chemotherapy; Drug labelling; Tomography, emission computed; Tomography, emission computed, single photon

Indexed keywords

5 ETHYNYLURACIL; ALKYLATING AGENT; ANTIANDROGEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; ANTINEOPLASTIC ANTIMETABOLITE; AROMATASE INHIBITOR; BLEOMYCIN; BUSULFAN; CAPECITABINE; CARMUSTINE; CISPLATIN; COLCHICINE; DAUNORUBICIN; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ENZYME INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NALPHA [N (2 CHLOROETHYL) N NITROSOCARBAMOYL]SARCOSINAMIDE; NITROSOUREA DERIVATIVE; PACLITAXEL; PLACEBO; RADIOISOTOPE; TAMOXIFEN; TEMOZOLOMIDE; TUBULIN MODULATOR; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; BRAIN TUMOR; BREAST CANCER; BREAST CARCINOMA; CANCER; CANCER TISSUE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DIGESTIVE SYSTEM CANCER; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG STRUCTURE; DRUG TISSUE LEVEL; DRUG TUMOR LEVEL; DRUG UPTAKE; GLIOBLASTOMA; HUMAN; ISOTOPE LABELING; LIVER METASTASIS; LUNG CARCINOMA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CARCINOMA; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANIMALS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; DRUG DESIGN; FORECASTING; HUMANS; ISOTOPE LABELING; MOLECULAR PROBE TECHNIQUES; NUCLEAR MEDICINE; RADIOPHARMACEUTICALS;

EID: 34447569397     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. 11C-labeling of busulphan. Int J Rad Appl Instrum [A] 1991;42:1055-9.
2. 11C]-busulfan in cynomolgus monkey and in the brain of a human patient. Cancer Chemother Pharmacol 1992;30:81-5.
3. Owens SE, Thatcher N, Sharma H, Adam N, Harrison R, Smith A et al. In vivo distribution studies of radioactively labelled platinum complexes; cis-dichlorodiammine platinum(II), cis-transdichlorodihydroxy-bis-(isopropylamine) platinum(IV),cis-dichlorobis-cyclopropylamine platinum(II), and cis-diammine1,1-cyclobutanedicarboxylate platinum(II) in patients with malignant disease, using a ganima camera. Cancer Chemother Pharmacol 1985;14: 253-7.
4. 191Pt-cisplatin. Acta Oncol 1999;38:221-8.
5. De Spiegeleer B, Slegers G, Vandecasteele C, Van den Bossche W, Schelstraete K, Claeys A et al. Microscale synthesis of nitrogen-13-labeled cisplatin. J Nucl Med 1986;27:399-403.
6. 13N]cisplatin PET to assess pharmacokinetics of intra-arterial versus intravenous chemotherapy for malignant brain tumors. J Nucl Med 1987;28:1844-52.
7. 11C-methyl]-8-carbamoyl- 3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one(temozolomide) for positron emission tomography (PET) studies. J Med Chem 2002; 45:5448-57.
8. Saleem A, Brown GD, Brady F, Aboagye EO, Osman S, Luthra SK et al. Metabolic activation of temozolomide measured in vivo using positron emission tomography. Cancer Res 2003;63:2409-15.
9. 18F-5-fluorouridine in rats. Eur J Nucl Med 1984;9:185-9.
10. 18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results. Nucl Med Biol 1996;23:33342.
11. Bading JR, Yoo PB, Fissekis JD, Alauddin MM, D'Argenio DZ, Conti PS. Kinetic modeling of 5-fluorouracil anabolism in colorectal adenocarcinoma: a positron emission tomography study in rats. Cancer Res 2003;63:3667-74.
12. 18F]Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl Med Biol 2004;31:1033-41.
13. Dimitrakopoulou A, Strauss LG, Clorius JH, Ostertag H, Schlag P, Heim M et al. Studies with positron emission tomography after systemic administration of fluorine-18-uracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1993;34:1075-81.
14. 18F-labeled fluorouracil positron emission tomography and the prognoses of colorectal carcinoma patients with metastases to the liver treated with 5-fluorouracil. Cancer 1998; 83:245-53.
15. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Irngartinger G, Oberdorfer F et al. Intravenous and intra-arterial oxygen-15-labeled water and fluorine-18-labeled fluorouracil in patients with liver metastases from colorectal carcinoma. J Nucl Med 1998;39:465-73.
16. Dimitrakopoulou-Strauss A, Strauss LG, Schlag P, Hohenberger P, Mohler M, Oberdorfer F et al. Fluorine-18-fluorouracil to predict therapy response in liver metastases from colorectal carcinoma. J Nucl Med 1998;39:1197-202.
17. 18F]fluorouracil. J Nucl Med 1998;39:1370-6.
18. Kisssel J, Port RE, Zaers J, Bellemann AM, Strauss LG, Haberkorn UO et al. Noninvasive determination of the arterial input function of an anticancer drug from dynamic PET scans using the population approach. Med Phys 1999;26:609-15.
19. Harte RJ, Matthews JC, O'ReiNy SM, Tilsley DW, Osman S, Brown G et al. Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. J Clin Oncol 1999;17:1580-8.
20. Saleem A, Yap J, Osman S, Brady F, Suttle B, Lucas SV et al. Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action. Lancet 2000;355:2125-31.
21. Aboagye EO, Saleem A, Cunningham VJ, Osman S, Price PM. Extraction of 5-fluorouracil by tumor and liver: a noninvasive positron emission tomography study of patients with gastrointestinal cancer. Cancer Res 2001;61:4937-41.
22. Umezawa H, Maeda K, Takeuchi T, Okami Y. New antibiotics, bleomycin A and B. J Antibiot (Tokyo) 1966;19:200-9.
23. Krohn KA, Meyers JM, DeNardo GL, DeNardo SJ. Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. J Nucl Med 1977;18:276-81.
24. 57Co-bleomycin in normal and tumor tissues. Strahlentherapie 1978;154:63-70.
25. Frohlich M, Henke E, Arnold W, Naundorf H, Gens J. Experimental research f6flowing intratumor bleomycin use in the nude mouse model of oral mucosa cancer and the clinical pilot study. Arch Geschwulstforsch 1986;56:125-34.
26. 57Co-bleomycin in sheep after intra-arterial injection in the head and neck region. Recent Results Cancer Res 1983;86:141-51.
27. 57Co-bleomycin in heat-treated rat tumors. Radiology 1983; 146:213-7.
28. 57Co-bleomycin in mice with chemically induced squamous cell carcinoma. Strahlentherapie 1979;155: 770-3.
29. Front D, Israel O, Iosilevsky G, Even-Sapir E, Frenkel A, Kolodny GM, et al. SPECT quantitation of cobalt-57 bleomycin delivery to human brain tumors. J Nucl Med 1988;29:187-94.
30. 55Co- bleomycin single photon scintigraphy. Eur J Nucl Med 1982;7:104-7.
31. 57Co-bleomycin scintigraphy in the detection of brain metastases of lung cancer. Clin Neurol Neurosurg 1988;90:109-11.
32. Even-Sapir E, Bettman L, Iosilevsky G, Milshtein D, Frenkel A, Kolodny GM et al. SPECT quantitation of cobalt-57-bleomycin to predict treatment response and outcome of patients with lung cancer. J Nucl Med 1994;35:1129-33.
33. Frohlich M, Henke E, Gens J, Seela W, Franke WG. Evaluation of intratumoral bleomycin application in a tumor model and in a clinical pilot study. Dtsch Z Mund Kiefer Gesichtschir 1990;14:456-62.
34. Zweit J, Carnochan P, Goodall R, Ott R. Nickel-57-doxorubicin, a potential radiotracer for pharmacokinetic studies using PET: production and radiolabelling. J Nucl Biol Med 1994;38:18-21.
35. 111In]DTPA-adriamycin in mammary tumor-bearing rats. Anticancer Drugs 1999;10:89-95.
36. Elsinga PH, Franssm EJ, Hendrikse NH, Fluks L, Weemaes AM, van der Graaf WT et al. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J Nucl Med 1996;37:1571-5.
37. 11C]BCNU evaluated by PET. J Nucl Med 1986; 27:775-80.
38. 11C)-HECNU: the hydroxyethyl analog of the chemotherapeutic agent BCNU. Int J Rad Appl Instrum 1991;42:441-6.
39. Conway T, Diksic M. Synthesis of "no-carrier-added" carbon-11 SarCNU: the sarcosinamide analog of the chemotherapeutic agent BCNU. J Nucl Med 1988;29:1957-60.
40. 11C-labelled BCNU and SarCNU in gliomas studied by PET. J Neurooncol 1991;10:47-55.
41. Brady F, Luthra SK, Brown G, Osman S, Harte RJ, Denny WA et al. Carbon-11 labelling of the antitumour agent N-[2-(dimethylamino)ethyllacridine-4-carboxamide (DACA) and determination of plasma metabolites in man. Appl. Radiat Isot 1997;48:487-92.
42. Gao M, MWer KD, Sledge GW, Zheng QH. Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers. Bioorg Med Chem Lett 2005; 15:3865-9.
43. Li C, Yu DF, Inoue T, Yang DJ, Tansey W, Liu CW et al. Synthesis, biodistribution and imaging properties of indium-111-DTPA-paclitaxel in mice bearing mammary tumors. J Nucl Med 1997;38: 1042-7.
44. Kiesewetter DO, Jagoda EM, Kao CH, Ma Y, Ravasi L, Shimoji K et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 2003;30:11-24.
45. 18F-paclitaxel in nonhuman primates. J Nucl Med 2003;44:1330-9.
46. Mehta BM, Levchenko A, Rosa E, Kim SW, Winnick S, Zhang JJ et al. Evaluation of carbon-14-colchicine biodistribution with whole-body quantitative autoradiography in colchicine-sensitive and -resistant xenografts. J Nucl Med 1996;37:312-4.
47. 11C-colchicine for PET imaging of multiple drug resistance. J Nucl Med 2000;41:493-501.
48. Yang DJ, Li C, Kuang LR, Price JE, Buzdar AU, Tansey W et al. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues. Life Sci 1994;55:53-67.
49. Delpassand ES, Yang DJ, Wallace S, Cherif A, Quadri SM, Price J et al. Synthesis, biodistribution, and estrogen receptor scintigraphy of indium-111-diethylenetriaminepentaacetic acid-tamoxifen analogue. J Pharm Sci 1996;85:553-9.
50. Shani J, Gazit A, Livshitz T, Biran S. Synthesis and receptor-binding affinity of fluorotamoxifen, a possible estrogen-receptor imaging agent. J Med Chem 1985;28:1504-11.
51. 123I-labeled 4-hydroxytamoxifen derivatives in rats with dimethylbenzanthracene-induced mammary carcinomas. Nucl Med Biol 1997;24: 719-22.
52. 18F]fluorotamoxifen to evaluate therapeutic responses in patients with breast cancer: preliminary study. Cancer Biother Radiopharm 1996;11:23545.
53. 11C-toremifene in rats bearing DMBA-induced mammary carcinoma. Pharmacol Toxicol 1989;64:373-7.
54. 18F]fluorine substitution at the 16alpha-position of fulvestrant (faslodex; ICI 182,780). Nucl Med Biol 2004;31:691-8.
55. Lee KC, Moon BS, Lee JH, Chung KH, Katzenellenbogen JA, Chi DY. Synthesis and binding affinities of fluoroalkylated raloxifenes. Bioorg Med Chem 2003;11:3649-58.
56. 11C]vorozolebinding assay. Steroids 1999;64:266-72.
57. 18F]-radiolabeled hydroxyflutamide derivatives. Bioorg Med Chem 2005;13:6195-205.
58. Minchinton A, Tannock I. Drug penetration in solid tumors. Nat Rev Cancer 2006;6:583-92.